Clinical Trials
17 trialsNCT04305054 2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04253080 2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT07476326 2026-04-03
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
NCT03293784 2026-03-30
TICIMEL
Institut Claudius Regaud
Phase 1 Completed
NCT03993379 2025-12-26
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
Phase 2 Terminated
NCT05751928 2025-07-08
NEO-MIMAJOR
Biocad
Phase 3 Active not recruiting
NCT05732805 2025-02-27
OCTAVA
Biocad
Phase 3 Active not recruiting
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT02535078 2024-07-24
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
Phase 1/2 Withdrawn
NCT02970981 2024-04-30
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NYU Langone Health
Phase 2 Completed
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03354962 2020-12-04
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
Institut Claudius Regaud
Phase 1/2 Terminated
NCT01216436 2015-05-25
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Duke University
Phase 1 Terminated
NCT00028431 2014-05-22
Novel Adjuvants for Peptide-Based Melanoma Vaccines
University of Southern California
Phase 1 Completed